ALTIUM
18.2.2020 15:32:10 CET | Business Wire | Press release
EMBEDDED WORLD — Today Altium, a global leader in PCB design software, announced the launch of a new cloud-based application that redefines the way that printed circuit board designs are shared between designers, part suppliers, and manufacturers.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200218005188/en/
The A365 Viewer, powered by the Altium 365 cloud platform, is a brand new, and innovative way to view and share electronic designs through a browser on any web-enabled desktop, phone or tablet. Schematics, PCB layout, and 3D visualization provide an interactive eCAD experience with no downloads or installations required. The A365 Viewer is part of Altium’s cloud strategy and newly launched Altium 365 cloud platform.
Simplicity is the Ultimate Sophistication
Until now, designers have been forced to share their PCB designs through PDFs or static images. With the new A365 Viewer, an interactive experience is created that retains all of the key relevant information that's typically lost when sharing static files. For example, the A365 Viewer allows users to search for, select, cross-probe and inspect components and nets while moving seamlessly between schematic, PCB and 3D views of their board.
Using the A365 Viewer requires no CAD tools or experience. The A365 Viewer is designed to work with multiple eCAD formats, currently supporting Autodesk® Eagle™ and Altium Designer™. Other popular PCB design software formats will be supported in the near future.
Easily Embedded on Your Website
Anyone can easily embed the viewer on their website, free of charge, by visiting https://www.altium.com/viewer/ . As an example, a well-known developer of electronics hardware and software kits, Arduino, is helping engineers and makers to easily and quickly visualize the PCB designs and assemblies available in their product kits, by embedding the A365 Viewer on the Arduino website .
"Adding the Altium 365 Viewer has significantly enhanced the user experience when navigating the product documentation in our website. Now Arduino users can freely browse schematics, PCB layout and even 3D models of the Arduino boards and modules online, without the need to download or install anything additional. The capability of being CAD-agnostic will shorty allow Arduino to add the online design viewer to every product page, including the ones designed in Autodesk Eagle. " - Fabio Violante, CEO, Arduino
Built-in Design IP Protection
The A365 Viewer protects the IP rights of design owners while retaining the CAD design details via a new process called Published Design Impression (PDI). The Viewer processes the design source files to create a Published Design Impression, or PDI. The PDI is a CAD-aware, perishable snapshot of the design that captures limited information such as components, net connectivity and basic geometrics, excluding design primitive data that would be required to fully comprehend and author changes to the design.
The design sources are discarded immediately after being used solely for the purpose of creating a PDI. The design is available for the duration of the user’s browser session and is automatically removed when the browser tab is closed.
Altium is demonstrating its A365 Viewer at the Embedded World 2020 trade show, Hall 4 stand 371, taking place at the Nuremberg Exhibition Center on February 25-27. To learn more visit: https://www.altium.com/viewer/
ABOUT ALTIUM
Altium LLC (ASX:ALU ), a global software company headquartered in San Diego, Calif., is accelerating the pace of innovation through electronics. From individual inventors to multinational corporations, more PCB designers and engineers choose Altium software to design and realize electronics-based products.
The growing demand for smart and connected products is driving advancements in electronics technology. Design trends are demonstrating the need for minimizing power, reducing package size and energy consumption, and prioritizing high-speed design. For over 30 years, Altium has been delivering software that maximizes the productivity of PCB designers and electrical engineers, from idea to board. Users are at the center of Altium’s R&D and business operations. With its unique Business-to-User approach, Altium is focused on developing software that is easy to use and implement, with solutions that enable innovation and deliver industry-leading user productivity.
Products include Altium Designer®, Altium Concord Pro™, Altium 365®, Altium NEXUS®, CircuitMaker®, CircuitStudio®, Octopart®, and TASKING®. To learn more about Altium, visit www.altium.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20200218005188/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom